TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9767555

Group type: EXPERIMENTAL
Intervention: Triple drug immunosuppressive regimen including CsA, azathioprine and corticosteroids
Number of subjects: 50

Group type: COMPARATOR
Intervention: Quadruple sequential combination of rabbit antithymocyte globulin (ATG) for 10 days, azathioprine, corticosteroids and delayed CsA
Number of subjects: 50

Group type: COMPARATOR
Intervention: ATG group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Triple regimen group
Number of subjects: 50
Study: 7874660

Group type: EXPERIMENTAL
Intervention: Marital therapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marital therapy in combination with antidepressants
Number of subjects: 0
Study: 3396702

Group type: EXPERIMENTAL
Intervention: High-dosage testosterone enanthate (TE) for 5 to 6 months
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (sesame oil) injections for 5 to 6 months
Number of subjects: 11
Study: 30791735

Group type: EXPERIMENTAL
Intervention: Yoga therapy (60 minutes once a week for 8 weeks)
Number of subjects: 58
Study: 27723486

Group type: EXPERIMENTAL
Intervention: Video exposure to a snake in a single context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video exposure to a snake in multiple contexts
Number of subjects: 0

Group type: COMPARATOR
Intervention: No exposure (control group)
Number of subjects: 0
Study: 25640834

Group type: EXPERIMENTAL
Intervention: Elementary school-based universal preventive intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 24060261

Group type: EXPERIMENTAL
Intervention: Demographic variables
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Arthritis-specific demographics (type, medication use)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Physical health-related variables
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Arthritis-specific symptoms
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Health behaviors
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Psychological variables
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Final model including all variables
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Older age, less than a high school education, rheumatoid arthritis, greater arthritis duration, taking steroids, taking narcotics, greater pain, greater stiffness, greater depressive symptoms, lower arthritis self-efficacy
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Male gender, fibromyalgia, excellent/very good health
Number of subjects: 396
Study: 21428240

Group type: EXPERIMENTAL
Intervention: Olanzapine film-coated tablet (test formulation)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Olanzapine orodispersible tablet (test formulation)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Reference formulations (brand formulations)
Number of subjects: 46
Study: 19270165

Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 179

Group type: COMPARATOR
Intervention: Flat inserts
Number of subjects: 179

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 179

Group type: COMPARATOR
Intervention: Physiotherapy plus orthoses
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 179
Study: 16288447

Group type: EXPERIMENTAL
Intervention: Mindfulness-based art therapy (MBAT)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 111
Study: 16009748

Group type: EXPERIMENTAL
Intervention: Go Sun Smart (GSS) program
Number of subjects: 26
Study: 11963648

Group type: EXPERIMENTAL
Intervention: Lidose formulation of fenofibrate (67 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lidose formulation of fenofibrate (200 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference micronized formulation of fenofibrate (67 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference micronized formulation of fenofibrate (200 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 48
Study: 9792152

Group type: EXPERIMENTAL
Intervention: Cisplatin, Methotrexate, and Vinblastine (CMV)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Methotrexate and Vinblastine (MV)
Number of subjects: 214
Study: 7623260

Group type: EXPERIMENTAL
Intervention: Tissue thickness > 1 mm
Number of subjects: 37

Group type: COMPARATOR
Intervention: Tissue thickness <= 1 mm
Number of subjects: 37
Study: 2541159

Group type: EXPERIMENTAL
Intervention: Cortisol (6 mg/h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ACTH (0.55 U/h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CRH (30 micrograms/h)
Number of subjects: 20
Study: 1101375

Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate/betamethasone phosphate
Number of subjects: 22

Group type: COMPARATOR
Intervention: Betamethasone acetate/betamethasone phosphate
Number of subjects: 22
Study: 31561272

Group type: EXPERIMENTAL
Intervention: CTG with EMD
Number of subjects: 41

Group type: COMPARATOR
Intervention: CTG only
Number of subjects: 41
Study: 30941975

Group type: EXPERIMENTAL
Intervention: Community-based intervention for increasing awareness of prostate cancer (PCa)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Knowledge about PCa treatment success
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Stage in which PCa is most frequently detected
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Preventive prostate examination
Number of subjects: 407
Study: 27874307

Group type: EXPERIMENTAL
Intervention: Needle-free injection device
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional needle and syringe
Number of subjects: 52
Study: 25759378

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Diabetes support and education (control)
Number of subjects: 1351
Study: 21947374

Group type: EXPERIMENTAL
Intervention: Combined spa therapy (mud packs and thermal baths) and rehabilitation (exercises in a thermal pool) for 10 sessions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 21692970

Group type: EXPERIMENTAL
Intervention: BoNT-A (Dysport) 40 units per site, total 400 units
Number of subjects: 153

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 153
Study: 19636051

Group type: EXPERIMENTAL
Intervention: Active HCV replication (detectable HCV RNA)
Number of subjects: 559

Group type: COMPARATOR
Intervention: No active HCV replication (undetectable HCV RNA)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Active HCV replication
Number of subjects: 559

Group type: COMPARATOR
Intervention: No active HCV replication
Number of subjects: 559
Study: 17542112

Group type: EXPERIMENTAL
Intervention: Daily iron treatment (5 mg elemental iron as ferrous sulfate per kg of body weight)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Weekly iron treatment (5 mg elemental iron as ferrous sulfate per kg of body weight)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Twice weekly iron treatment (5 mg elemental iron as ferrous sulfate per kg of body weight)
Number of subjects: 134
Study: 15381643

Group type: EXPERIMENTAL
Intervention: Carvedilol (n=505)
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Placebo (n=506)
Number of subjects: 1011
Study: 11585004

Group type: EXPERIMENTAL
Intervention: Infliximab (Remicade)
Number of subjects: 150000
Study: 9169251

Group type: EXPERIMENTAL
Intervention: Soluble aspirin formulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Plain paracetamol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Soluble paracetamol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 12
Study: 8192173

Group type: EXPERIMENTAL
Intervention: 0.5% podofilox self-administered twice daily for 3 consecutive days per week for 4 weeks (stage 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.5% podofilox self-administered once daily for 3 days per week for 8 weeks (stage 2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (stage 2)
Number of subjects: 100
Study: 3285883

Group type: EXPERIMENTAL
Intervention: Amoxycillin‐clavulanic acid (1.2 g intravenous)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Metronidazole (1 g suppository)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Amoxycillin‐clavulanic acid
Number of subjects: 300

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 300
Study: 30276206

Group type: EXPERIMENTAL
Intervention: GC Tooth Mousse Plus
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Clinpro™ White Varnish
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Duraphat® Varnish
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Pro‐Relief™ dentifrice
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Biodentine™
Number of subjects: 70
Study: 28107101

Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg orally three times daily for 28 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days
Number of subjects: 90
Study: 25742888

Group type: EXPERIMENTAL
Intervention: 10 mg enalapril plus 0.8 mg FA (high‐FA group)
Number of subjects: 480

Group type: COMPARATOR
Intervention: 10 mg enalapril (control group)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 10 mg enalapril plus 0.4 mg FA (low‐FA group)
Number of subjects: 480
Study: 23004926

Group type: EXPERIMENTAL
Intervention: Methantheline bromide (MB) 50 mg three times daily
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study: 21045183

Group type: EXPERIMENTAL
Intervention: Low-dose helical computed tomography (CT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chest radiography
Number of subjects: 0
Study: 18679709

Group type: EXPERIMENTAL
Intervention: Polyethylene stent
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydrophilic hydromer-coated polyurethane stent
Number of subjects: 30
Study: 17342883

Group type: EXPERIMENTAL
Intervention: Amino acid supplementation (9 essential and 3 non‐essential amino acids)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14628974

Group type: EXPERIMENTAL
Intervention: Risperidone (4-12 mg/day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Olanzapine (10-20 mg/day)
Number of subjects: 39
Study: 10971659

Group type: EXPERIMENTAL
Intervention: 6-mg Sirdalud
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: 12-mg Sirdalud MR
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 8884967

Group type: EXPERIMENTAL
Intervention: Accelerated 7 days per week fractionation schedule (arm A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional 5 days per week treatment (arm B)
Number of subjects: 44
Study: 1571205

Group type: EXPERIMENTAL
Intervention: Prednisone, 40 mg/m2, given every other day as a single morning dose
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lactose, 40 mg/m2, given every other day as a single morning dose (Control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lactose (Control)
Number of subjects: 80
Study: 3880781

Group type: EXPERIMENTAL
Intervention: Local application of dimethylsulfoxide (DMSO) solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 20
Study: 31165506

Group type: EXPERIMENTAL
Intervention: Intraurethral self‐retaining device (ISRD)
Number of subjects: 177
Study: 30242322

Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia After Pediatric Cardiac Arrest In‐Hospital (THAPCA‐IH) and Out‐of‐Hospital (THAPCA‐OH) trials
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Neuropsychological testing including the Mullen Scales of Early Learning (Mullen) and Wechsler Abbreviated Scale of Intelligence (WASI)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: VABS‐II (Vineland Adaptive Behavior Scales, Second Edition)
Number of subjects: 222
Study: 26949875

Group type: EXPERIMENTAL
Intervention: WSM (web-based mindfulness stress management program)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: WSM with group support
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: WSM with group and expert clinical support
Number of subjects: 161

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 161
Study: 25005452

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg orally once daily
Number of subjects: 250

Group type: COMPARATOR
Intervention: Dose-adjusted oral vitamin K antagonist (VKA)
Number of subjects: 250
Study: 22465911

Group type: EXPERIMENTAL
Intervention: Biennial LDCT screening
Number of subjects: 4099

Group type: EXPERIMENTAL
Intervention: Annual LDCT screening
Number of subjects: 4099

Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 4099
Study: 20423395

Group type: EXPERIMENTAL
Intervention: Healthcare professional‐led rehabilitation programme
Number of subjects: 58

Group type: COMPARATOR
Intervention: Self‐managed rehabilitation programme
Number of subjects: 58
Study: 18924480

Group type: EXPERIMENTAL
Intervention: Vejnović modification
Number of subjects: 1886

Group type: COMPARATOR
Intervention: Common operative technique
Number of subjects: 1886
Study: 15829577

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Infliximab + Methotrexate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Methotrexate monotherapy
Number of subjects: 42
Study: 11879260

Group type: EXPERIMENTAL
Intervention: Sildenafil (100-mg single dose)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 11686667

Group type: EXPERIMENTAL
Intervention: 24-hour on-site catheterization facilities
Number of subjects: 15078

Group type: COMPARATOR
Intervention: Day-only on-site catheterization facilities
Number of subjects: 15078

Group type: COMPARATOR
Intervention: No on-site catheterization facilities
Number of subjects: 15078
Study: 9226059

Group type: EXPERIMENTAL
Intervention: loratadine (10 mg OD)
Number of subjects: 139
Study: 7904786

Group type: EXPERIMENTAL
Intervention: Roxatidine acetate (150 mg once daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Ethanol (0.3 g/kg)
Number of subjects: 11
Study: 3523713

Group type: EXPERIMENTAL
Intervention: trimethoprim‐sulfamethoxazole (160 mg/800 mg daily)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: trimethoprim (200 mg daily)
Number of subjects: 433

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: bicozamycin (500 mg four times daily)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: norfloxacin (400 mg daily)
Number of subjects: 433
Study: 29567630

Group type: EXPERIMENTAL
Intervention: Enalapril started before chemotherapy (prevention arm)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Enalapril started only in patients with an increase in troponin during or after chemotherapy (troponin-triggered arm)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Both groups (prevention and troponin-triggered)
Number of subjects: 273
Study: 29354992

Group type: EXPERIMENTAL
Intervention: Moxibustion at Geshu (BL 17), once a day for 4 sessions (2 weeks each session)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Oral administration of cilostazol, 50 mg, twice a day for 4 sessions (2 weeks each session)
Number of subjects: 70
Study: 25736283

Group type: EXPERIMENTAL
Intervention: Evacetrapib 130 mg/d following a high-fat breakfast
Number of subjects: 40

Group type: COMPARATOR
Intervention: Evacetrapib 130 mg/d following a 10-hour fast
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Evacetrapib 130 mg/d (both fed and fasted states)
Number of subjects: 40
Study: 23444983

Group type: EXPERIMENTAL
Intervention: Lower-carbohydrate diet (41:19:40% energy from carbohydrate/protein/fat)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard diet (55:18:27% energy from carbohydrate/protein/fat)
Number of subjects: 30
Study: 21178093

Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP) containing 2.5 mg iron as NaFeEDTA and 2.5 mg zinc, added to high-phytate maize porridge 5 days/week for 23 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Unfortified carrier added to high-phytate maize porridge
Number of subjects: 200
Study: 19064623

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02D vaccine
Number of subjects: 340

Group type: COMPARATOR
Intervention: Hepatitis B vaccine
Number of subjects: 340
Study: 16552215

Group type: EXPERIMENTAL
Intervention: Intensive glycemic management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyperglycemia during cardiac surgery
Number of subjects: 0
Study: 14689177

Group type: EXPERIMENTAL
Intervention: Psycho-educational and therapeutic alliance intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10975476

Group type: EXPERIMENTAL
Intervention: Double filtration plasmapheresis (DF)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Immunoadsorption plasmapheresis (IA)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Daily schedule of plasmapheresis
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Optimal number of PP sessions
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Factors correlating with better clinical response
Number of subjects: 94
Study: 9368546

Group type: EXPERIMENTAL
Intervention: Early outpatient treatment for PTSD for 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elderly people
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychosocial factors
Number of subjects: 0
Study: 1391980

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with tamoxifen and medroxyprogesterone acetate
Number of subjects: 0
Study: 29940126

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 136

Group type: COMPARATOR
Intervention: Conventional subcutaneous insulin therapy
Number of subjects: 136
Study: 26690641

Group type: EXPERIMENTAL
Intervention: ESM self‐monitoring intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 102
Study: 25609011

Group type: EXPERIMENTAL
Intervention: Zovirax 200 mg dispersible tablets co-administered with 400 mg chitosan HCl
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zovirax 200 mg dispersible tablets co-administered with 1000 mg chitosan HCl
Number of subjects: 12

Group type: COMPARATOR
Intervention: Zovirax only
Number of subjects: 12
Study: 23400856

Group type: EXPERIMENTAL
Intervention: Color characters (e.g., hong2, 'red')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homophones of the color characters (S+T+) (e.g., hong2, 'flood')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different-tone homophones (S+T-) (e.g., hong1, 'boom')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Characters that shared the same tone but differed in segments with the color characters (S-T+) (e.g., ping2, 'bottle')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral characters (S-T-) (e.g., qian1, 'leading through')
Number of subjects: 0
Study: 21911098

Group type: EXPERIMENTAL
Intervention: Supportive individual psychotherapy followed by combined psychodynamic and cognitive‐behavioral group therapy (total of 28 sessions).
Number of subjects: 569

Group type: COMPARATOR
Intervention: One psychosocial counseling session.
Number of subjects: 569
Study: 17764465

Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Regular human insulin (RHI)
Number of subjects: 18
Study: 16642610

Group type: EXPERIMENTAL
Intervention: Deep needling at Ermen (TE 21), Tinggong (SI 19), and Tinghui (GB 2) combined with body acupuncture
Number of subjects: 47

Group type: COMPARATOR
Intervention: Shallow needling at Ermen (TE 21), Tinggong (SI 19), and Tinghui (GB 2) combined with body acupuncture
Number of subjects: 47
Study: 12716487

Group type: EXPERIMENTAL
Intervention: rHuIFN-gamma (100 microg subcutaneously)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 11134132

Group type: EXPERIMENTAL
Intervention: GHRP-2 alone
Number of subjects: 9

Group type: COMPARATOR
Intervention: GHRH alone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Acipimox + GHRH
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Acipimox + GHRP-2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Basal FFAs
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: GHRP-2 administration
Number of subjects: 9
Study: 8800308

Group type: EXPERIMENTAL
Intervention: Intravenous iloprost 0.5‐2.0 ng/kg/min for 6 h from 8 to 13 days
Number of subjects: 12
Study: 1464049

Group type: EXPERIMENTAL
Intervention: Topical capsaicin pre-treatment
Number of subjects: 12
Study: 6397182

Group type: EXPERIMENTAL
Intervention: High humidity atmosphere
Number of subjects: 16

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 16
Study: 31830082

Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gait
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gait (Amputee Intact vs. Residual Knee)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gait (Amputee Residual vs. Intact Knee)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Elliptical (Amputee Residual vs. Intact Knee)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gait (Amputee vs. Control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gait (Amputee)
Number of subjects: 20
Study: 29433385

Group type: EXPERIMENTAL
Intervention: IV lidocaine infusion (bolus 1.5 mg/kg followed by a continuous infusion at the rate of 2 mg/kg/hr until skin closure)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IV lidocaine infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (0.9% NaCl solution)
Number of subjects: 60
Study: 26306716

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation treatment (MRT)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 122